Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Nov 2022

Swami Umang, Graf Ryon P, Nussenzveig Roberto H, Fisher Virginia, Tukachinsky Hanna, Schrock Alexa B, Li Gerald, Ross Jeffrey S, Sayegh Nicolas, Tripathi Nishita, Mathew Thomas Vinay, Oxnard Geoffrey R, Antonarakis Emmanuel S, Agarwal Neeraj

Abstract excerpt

PURPOSE: Intensification of androgen deprivation therapy (ADT) with either docetaxel or androgen receptor axis-targeted therapies (ARAT) are the current standard of care for patients with metastatic castration-sensitive prostate cancer (mCSPC). However, biomarkers guiding treatment selection are lacking. We hypothesized that ADT intensification with ARAT, but not with docetaxel, would be associated with improved...

Topics

Join the communities discussing this publication.

Androgen Antagonists
Biomarkers
Disease-Free Survival
Docetaxel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Receptors, Androgen

Treatment Outcome

Source

Identifiers

PMID: 36088616
DOI: 10.1158/1078-0432.CCR-22-2228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.PMID 36088616Read ↗

Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).Semantic proximity Read ↗

SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer.Semantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?Semantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?Semantic proximity Read ↗

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.Semantic proximity Read ↗

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.Semantic proximity Read ↗

Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerSemantic proximity Read ↗

Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.Semantic proximity Read ↗

Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancerSemantic proximity Read ↗

Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in EuropeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.